Odonate Therapeutics, Inc. (ODT): Price and Financial Metrics
GET POWR RATINGS... FREE!
ODT Stock Price Chart Interactive Chart >
ODT Price/Volume Stats
|Current price||$3.78||52-week high||$11.62|
|Prev. close||$3.77||52-week low||$2.80|
|Day high||$3.83||Avg. volume||3,279,939|
|50-day MA||$3.41||Dividend yield||N/A|
|200-day MA||$4.10||Market Cap||145.56M|
Odonate Therapeutics, Inc. (ODT) Company Bio
Odonate Therapeutics, LLC develops therapeutics to enhance the lives of patients with cancer in the United States. It is developing Tesetaxel, a novel chemotherapy agent that has completed Phase II clinical trials for patients with advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
ODT Latest News Stream
|Loading, please wait...|
ODT Latest Social Stream
View Full ODT Social Stream
Latest ODT News From Around the Web
Below are the latest news stories about Odonate Therapeutics Inc that investors may wish to consider to help them evaluate ODT as an investment opportunity.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2020.
Craig Johnson Is The Independent Director of Odonate Therapeutics, Inc. (NASDAQ:ODT) And Just Spent US$51k On Shares
Even if it's not a huge purchase, we think it was good to see that Craig Johnson, the Independent Director of Odonate...
Is Odonate Therapeutics, Inc. (NASDAQ:ODT) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Jeffrey Vacirca to its Board of Directors to help guide the company as it seeks commercial approval following announcement of positive Phase 3 data from the PROTECTIVE-2 study of plinabulin in combination with pegfilgrastim for protection against chemotherapy-induced neutropenia. “We are delighted to welcome Dr. Vacirca as a member of our Board of Directors, especially given his impressive leadership within the oncology community,” said Dr. Lan Huang, Founder and Chief Executive Officer of BeyondSpring. “In addition to his many years as an accomplish...
ODT Price Returns